Abstract Details

Title Psychometric Evaluation of the Functional Impact of Migraine Questionnaire Within the COMPEL Trial

Topic Headache

Presentation(s) P14 - Poster Session 14 (8:00 AM-9:00 AM)

Poster/Presentation
Number 7-007

Objective This analysis evaluated the psychometric properties of the Functional Impact of Migraine Questionnaire (FIMQ; formerly Assessment of Chronic Migraine Impacts) in patients with chronic migraine (CM).

Background The FIMQ is a 20-question migraine-specific HRQoL measure with a 1-week recall interval, developed based on patient and clinician input using qualitative research methods.

Design/Methods For this psychometric evaluation, patient-reported outcome data from COMPEL (NCT01516892) were prospectively collected; data from day 1 and week 48 were used. Factor structure, reliability, validity, and ability to detect change were evaluated.

Results Seven-hundred thirteen CM patients provided baseline data and 506 provided data at the 48-week follow-up. Analysis of item-level results and clinical guidance of the 24 FIMQ items led to the removal of 4 items for redundancy, ceiling, or floor effects. Exploratory and confirmatory factor analyses conducted in an item response theory framework confirmed an overall domain (CFI=0.92, TLI=0.87, RMSEA=0.07) and 3 subdomains: activity impairment (14 items), emotional functioning (3 items), and cognitive functioning (3 items). The scores of the final 20 items were standardized on a 0-to-100 scale, with higher scores indicating greater levels of impairment. The FIMQ demonstrated excellent internal consistency across the 3 subdomains (Cronbach’s alpha range from 0.84 to 0.95). The FIMQ significantly differentiated across all MIDAS disability levels at week 48, supporting known groups validity. Concurrent validity was supported based on correlations with selected domains of the Migraine-Specific Quality of Life questionnaire v2.1 (range -0.69 to -0.82) and the 6-item Headache Impact Test (HIT-6; range 0.56 to 0.70). Anchor-based analyses with HIT-6 and distribution-based results indicated that the FIMQ detected within-patient treatment change over 48 weeks.

Conclusions The FIMQ measures important domains for CM patients, including activity impairment, emotional functioning, and cognitive functioning. The FIMQ demonstrated good reliability, validity, and ability to detect change in CM patients.

Authors/Disclosures
Pranav Gandhi PRESENTER	Pranav Gandhi has received personal compensation for serving as an employee of AbbVie. Pranav Gandhi has stock in AbbVie Inc.
Richard B. Lipton, MD, F�鶹��ýӳ�� (Albert Einstein College of Medicine)	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.
	No disclosure on file
Donald Bushnell	No disclosure on file
	No disclosure on file
Hema Viswanathan	Ms. Viswanathan has received personal compensation for serving as an employee of Allergan plc. Ms. Viswanathan has received personal compensation for serving as an employee of Precision Medicine Group. Ms. Viswanathan has received stock or an ownership interest from Allergan plc. Ms. Viswanathan has received stock or an ownership interest from Precision Medicine Group.

�鶹��ýӳ��

�鶹��ýӳ��